This activity is expired and is no longer available for CME credit.


Using the Latest Clinical Advances to Guide Your Practice: A Multidisciplinary Tumor Board

Author(s)/Faculty: Michael J. Birrer, MD, PhD; Edward S. Kim, MD, FACP; Joyce O'Shaughnessy, MD
Release Date: 7/8/2019Expiration Date: 7/7/2020
Credit Type: CMENumber of Credits: 0
Content Type: VideoProvider:
The treatment paradigm for the management of patients with advanced cancer has changed dramatically within recent years due to the discovery, clinical evaluation, and approval of immune checkpoint inhibitors and targeted therapies. With the approval of these novel therapies, selection and sequencing of optimal treatment strategies for individual patients has become more challenging. The utilization of specific biomarkers is imperative in these patients with advanced cancer to guide optimal treatment selection for prolonged survival and quality of life benefits. In this CME activity, experts in the fields of lung, breast, and ovarian cancer will utilize case studies to guide the integration of biomarker testing and selection of appropriate therapy into treatment algorithms for patients with advanced cancer.